Want to take quizzes and track your credits?
A CDC analysis has shown that a single dose of the Pfizer-BioNTech COVID-19 vaccine protected medically vulnerable nursing home residents as well as it did general adult populations that were evaluated in other efficacy and effectiveness studies.
The analysis helps fill a data gap about vaccine effectiveness in this high-risk group—generally older, frail adults with underlying health conditions—who were left out of COVID-19 vaccine trials. Excluding older adults from the trials raised questions about how well nursing home residents would respond to vaccination.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
By analyzing the Pfizer-BioNTech vaccine’s performance during a late January outbreak at 2 Connecticut skilled nursing facilities, investigators from the CDC and the Connecticut Department of Public Health provided real-world data about this vulnerable population. A review of 463 residents’ charts showed that the vaccine was 63% effective during the period that stretched from 14 days after their first shot until 7 days after their second.
You currently have no searches saved.